Journal: eClinicalMedicine
Article Title: Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan
doi: 10.1016/j.eclinm.2026.103768
Figure Lengend Snippet: Stromal Caveolin-1 (Cav-1) expression and survival outcome in gastric cancer. (A–D) Representative immunohistochemistry (IHC) images of stromal Cav-1 expression. (A) IHC Score 0: negative staining. (B) IHC Score 1+: weak to moderate staining, less intense than vascular endothelium. (C) IHC Score 2+: staining intensity comparable to vascular endothelium. (D) IHC Score 3+: strong staining, more intense than vascular endothelium. (E–H) Kaplan–Meier survival curves stratified by stromal Cav-1 expression. (E) Overall survival (OS) in the solvent-based paclitaxel (sb-PTX) + ramucirumab (RAM) arm. (F) Progression-free survival (PFS) in the sb-PTX + RAM arm. (G) OS in the nab-paclitaxel (nab-PTX) + RAM arm. (H) PFS in the nab-PTX + RAM arm.
Article Snippet: Cav-1 expression was assessed by immunohistochemistry (IHC) using a specific anti-Cav-1 monoclonal antibody (D46G3, Cell Signaling Technology, Danvers, MA, USA; 1:800) and scored based on staining intensity in the tumour stroma as follows: 0 (negative), 1+ (weak), 2+ (comparable to vascular endothelium), and 3+ (stronger than endothelium).
Techniques: Expressing, Immunohistochemistry, Negative Staining, Staining, Solvent